HIMS-NOVO Partnership Removes Key Legal Overhang<\/p>\n
JPMorgan initiated coverage of Hims & Hers with an \u2018Overweight\u2019 rating and a price target of $35, according to The Fly. This represents a near 25% upside from the stock\u2019s closing price on Thursday.<\/p>\n
Analyst Cory Carpenter believes Hims & Hers recent partnership with Novo Nordisk \u201ccould mark a turning point,\u201d easing key legal concerns and positioning the company as a broader platform spanning branded, generic, and compounded offerings.<\/p>\n
In March, Novo Nordisk teamed<\/a> up with Hims & Hers, allowing the telehealth platform to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices, while discontinuing the promotion of compounded GLP-1 drugs.<\/p>\n This came after Novo sued Hims & Hers for patent infringement after HIMS launched a $49-per-month compounded version of Wegovy, claiming it used the same active ingredient as the branded drug.<\/p>\n Analyst Sees Compelling Path For Upside<\/p>\n The brokerage noted that the company has built a leading direct-to-consumer healthcare platform, serving around 2.5 million subscribers across areas such as weight loss, women\u2019s health, erectile dysfunction, hair loss, testosterone, and an expanding presence in international markets.<\/p>\n Carpenter stated that a steadier GLP-1 business, progress toward peptide legalization, an expected revenue rebound in the second half, and the potential for additional branded partnerships together create a \u201ccompelling catalyst path\u201d for upside.<\/p>\n Hims & Hers also expanded<\/a> its GLP-1 offerings on its platform to include Eli Lilly drugs such as Zepbound, Mounjaro, and Foundayo.<\/p>\n However, HIMS is facing intensifying competition after Amazon expanded its GLP-1 management program through its One Medical platform, while rival telehealth platform Ro introduced major price cuts to its weight-loss membership program.<\/p>\n How Did Retail Traders React?<\/p>\n Retail sentiment on Stocktwits turned \u2018bullish\u2019 from \u2018extremely bullish\u2019 a day earlier, while message volumes remained \u2018extremely high.\u2019<\/p>\n One user said HIMS\u2019 chart is intact and the stock could climb to \u201cat least\u201d $40.<\/p>\n Another user noted that the short float is still high.<\/p>\n The stock has shed around 17% so far in 2026.<\/p>\n Read also: Why Is OGN Stock Rising In Pre-Market Today?<\/a><\/p>\n For updates and corrections, email newsroom[at]stocktwits[dot]com.<\/p>\n
![\"Follow](\"https:\/\/chunks-prd.stocktwits-cdn.com\/_next\/static\/media\/google-news-icon.d9c2bfd1.svg\"\/){kind=icon}
<\/a><\/p>\n